Shivom Joins Consortia on Horizon 20/20 TranSYS €EUR4 Million Grant

Shivom joins European consortia of clinical and innovative tech organisations on Horizon 20/20 TranSYS Programme. The €4 Million Grant will be used to fund 15 Early Stage Research (“ESR”) projects.

London, United Kingdom – June 27, 2019 – Shivom Ventures Limited (“Shivom”), a biotechnology data and analysis company optimising the way DNA is shared, secured and analysed through blockchain and AI technology, joins European consortium of clinical and innovative tech organisations on Horizon 20/20 TranSYS Programme. The €EUR4 Million Grant will be used to fund 15 Early Stage Research (“ESR”) projects seeking to advance and improve diagnostics, disease risk and treatment management, clinical sampling and more targeted therapeutic areas.

TranSYS research projects focus on “Integrating Big Data and ICT Solutions” and “Translating Basic to Clinical Research”. These areas are highlighted in the International Consortium for Personalised Medicine (ICPerMed) 2017 Action Plan4 as key challenges to develop new diagnostics, treatments, and healthcare approaches, to benefit European citizens and society. Part of the funds from the grant will be set aside for Shivom to work with each of these ESR’s to implement Shivom’s blockchain and AI-powered solutions all the while developing their own clinical research programme focusing on methylation events within Cancer and sports medicine. Shivom was picked for this project in particular because of their strong use case for data compliance and patient confidentiality. Additionally, the Horizon 20/20 programme will allow for recruiting a Clinical AI PhD student which will be supervised by Dr Darrol Baker.

“The molecular identification, characterization and secure patient consent for data use is a key measure within the realms of precision medicine and the prevention of ‘walling’ of genotypic and phenotypic data globally,” said Dr Darrol Baker, Head of Bioinformatics for Shivom. “Existing data in today’s digital universe offer tremendous opportunities to achieve this but for extracting insights and information from multiple heterogeneous and interdependent data in precision medicine, requires new systems analytics, moving beyond classical AI, algorithmic or mechanical processes and validation against disease models. The Horizon 20/20 TranSYS research projects focus on Integrating Big Data and ICT Solutions and Translating Basic to Clinical Research. Shivom’s clinical blockchain AI solutions and the TranSys programme offer a unique 4-year window to explore and innovate global blockchain precision medicine.”

For more information about Shivom please visit here
To read more about our affiliation with Living DNA please visit here
To read more about our affiliation with Vitl please visit here
To read more about our affiliation with Chronomics please visit here

About Shivom
Shivom is a biotechnology data and analysis company optimising the way DNA is shared, secured and analysed. By utilising innovative technologies such as blockchain and machine-learning algorithms, we are able to democratise genomics.

Our mission is to bring exponential value to our end-users within the genomics industry. We believe that the unique combination of our in-depth knowledge for genomics, mixed with deep-rooted backgrounds in cryptography and AI is essential in the democratisation of genomics and healthcare data.

Learn more about our direct-to-consumer solutions here

Shivom Social Channels:
Official Homepage: shivom.io
Twitter (English): @projectshivom
Youtube: Shivom’s Channel
Telegram: Shivom Announcements
Facebook: @projectshivom
Instagram: @projectshivom
Medium: Shivom Official
LinkedIn: @projectshivom

About Horizon 20/20
Horizon 2020 is the financial instrument implementing the Innovation Union, a Europe 2020 flagship initiative aimed at securing Europe’s global competitiveness.

Seen as a means to drive economic growth and create jobs, Horizon 2020 has the political backing of Europe’s leaders and the Members of the European Parliament. They agreed that research is an investment in our future and so put it at the heart of the EU’s blueprint for smart, sustainable and inclusive growth and jobs.

By coupling research and innovation, Horizon 2020 is helping to achieve this with its emphasis on excellent science, industrial leadership and tackling societal challenges. The goal is to ensure Europe produces world-class science, removes barriers to innovation and makes it easier for the public and private sectors to work together in delivering innovation.

Horizon 2020 is open to everyone, with a simple structure that reduces red tape and time so participants can focus on what is really important. This approach makes sure new projects get off the ground quickly – and achieve results faster.

The EU Framework Programme for Research and Innovation will be complemented by further measures to complete and further develop the European Research Area. These measures will aim at breaking down barriers to create a genuine single market for knowledge, research and innovation.

For more information about Horizon 20/20 and it’s research programmes please visit https://ec.europa.eu/programmes/horizon2020/en